Clinical Pharmacokinetics of Prazosin - 1985
Authors:
- 1 January 1985
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 10 (2) , 144-154
Abstract
Prazosin is a selective α1-adrenoceptor antagonist which is useful alone or in combination for the treatment of hypertension and heart failure. Unlike many other antihypertensive drugs, the action of prazosin appears to be closely related to its concentration in plasma or whole blood. Prazosin is variably absorbed, is subject to first-pass metabolism, and is eliminated almost entirely as metabolites of much lower hypotensive activity than the parent drug. Prazosin is highly bound to plasma and tissue proteins. The influences of renal, hepatic and cardiac disease on the disposition of prazosin are reviewed, as are the effects of pregnancy and ageing. The optimum use of prazosin in clinical practice depends on an understanding of the pharmacokinetic properties of the drug.Keywords
This publication has 48 references indexed in Scilit:
- Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metaboliteJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Prazosin plasma concentration and blood pressure reduction.Hypertension, 1982
- Pharmacokinetic and Pharmacodynamic Studies with Prazosin in Chronic Heart FailureJournal of Cardiovascular Pharmacology, 1981
- Clinical Pharmacokinetics of PrazosinClinical Pharmacokinetics, 1980
- Pharmacokinetics of Prazosin in Normotensive Subjects After Low Oral DosesClinical Pharmacokinetics, 1980
- Prazosin First-Pass Metabolism and Hepatic Extraction in the DogJournal of Cardiovascular Pharmacology, 1979
- Hepatic First-pass Metabolism in Liver DiseaseClinical Pharmacokinetics, 1979
- Pharmacokinetics of Prazosin in ManThe Journal of Clinical Pharmacology, 1978
- Altered Hepatic Blood Flow and Drug Disposition1Clinical Pharmacokinetics, 1976
- Prazosin in normal subjects: plasma levels, blood pressure and heart rate [letter].1976